For the quarter ending 2025-09-30, EW made $1,553,100K in revenue. $291,100K in net income. Net profit margin of 18.74%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net sales | 1,553,100 | 1,532,200 | 1,412,700 | 1,101,000 |
| Cost of sales | 345,200 | 344,400 | 301,600 | 183,700 |
| Gross profit | 1,207,900 | 1,187,800 | 1,111,100 | 917,300 |
| Selling, general, and administrative expenses | 514,600 | 502,000 | 465,700 | 427,300 |
| Research and development expenses | 280,700 | 276,200 | 254,600 | 241,800 |
| Certain litigation expenses | 90,400 | 15,500 | 10,900 | 12,600 |
| Change in fair value of contingent consideration liabilities | -12,500 | - | - | 0 |
| Restructuring charges and separation costs (note 3) | 100 | - | - | - |
| Separation costs (note 3) | - | 4,200 | 4,200 | 15,250 |
| Intangible assets impairment charges | 40,000 | - | - | - |
| Other operating (income) expense, net | 12,500 | 21,300 | 19,100 | 51,150 |
| Operating income, net | 307,100 | 411,200 | 394,800 | 271,500 |
| Interest expense | - | - | - | 4,950 |
| Interest income | - | - | - | 49,150 |
| Interest income, net | 38,600 | 37,400 | 36,500 | - |
| Loss on impairment | - | 47,100 | - | - |
| Loss on impairment (note 6) | 0 | - | - | - |
| Other non-operating income, net | 2,700 | -1,300 | 2,600 | 33,600 |
| Income from continuing operations before provision for income taxes | 348,400 | 400,200 | 433,900 | 349,300 |
| Provision for income taxes | 56,100 | 64,300 | 70,300 | 32,800 |
| Net income from continuing operations | 292,300 | 335,900 | 363,600 | 333,750 |
| Net sales | 15,900 | - | - | - |
| Cost of sales | 9,200 | - | - | - |
| Gross profit | 6,700 | - | - | - |
| Selling, general, and administrative expenses | 5,900 | - | - | - |
| Research and development expenses | 1,400 | - | - | - |
| Separation costs | 1,900 | - | - | - |
| Operating loss, net | -2,500 | - | - | - |
| Other non-operating (income) expense, net | 0 | - | - | - |
| (loss) income from discontinued operations before provision for income taxes | -2,500 | - | - | - |
| (benefit) provision from income taxes from discontinued operations | -500 | - | - | - |
| (loss) income from discontinued operations, net of tax | -2,000 | -4,400 | -7,200 | 33,900 |
| Net income | 290,300 | 331,500 | 356,400 | 384,300 |
| Net loss attributable to noncontrolling interest | -800 | -1,700 | -1,600 | -1,300 |
| Net income attributable to edwards lifesciences corporation | 291,100 | 333,200 | 358,000 | 385,600 |
| Basic (in shares) | 584,700,000 | 587,000,000 | 586,900,000 | -1,203,200,000 |
| Basic earnings per share (in dollars per share) | 0.5 | 0.57 | 0.61 | 0.65 |
| Diluted (in shares) | 585,700,000 | 587,900,000 | 587,800,000 | -1,207,200,000 |
| Diluted earnings per share (in dollars per share) | 0.5 | 0.56 | 0.61 | 0.65 |
Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp (EW)